For citizens

For companies

For medical specialists

EMA restricts use of multiple sclerosis medicine Zinbryta

Restrictions are provisional measures while review of liver safety is ongoing

The European Medicines Agency (EMA) is provisionally restricting the use of the multiple sclerosis medicine Zinbryta (daclizumab) to patients with highly active relapsing disease that has failed to respond to certain other treatment, and to patients with rapidly evolving relapsing disease who cannot be treated with other medicines.

More information:

EMA restricts use of multiple sclerosis medicine Zinbryta